Clinical characteristics of patients with suspected Alzheimer’s disease within a CSF Aß-ratio grey zone

Table 2 Association measures between Aß_1-₄₂ concentration in CSF, neuropsychological performance and MRI visual ratings per group

	Aß₄₂ concentration (pg/ml)
	Grey Zone			Low Aβ_1-42			AD
	r_s	95% CI		r_s	95% CI		r_s	95% CI
	r_s	LL	UL	r_s	LL	UL	r_s	LL	UL
Neuropsychological measures
MMSE (total)	0.53	0.31	0.70	0.69**	0.48	0.83	− 0.04	− 0.27	0.19
MoCA (total)	0.52	0.31	0.70	0.78**	0.61	0.88	0.09	− 0.16	0.32
Trail Making Test -Part A, z-score	0.18	− 0.12	0.46	0.53**	0.18	0.76	0.31*	0.01	0.56
Trail Making Test—Part B, z-score	− 0.69**	− 0.77	− 0.34	0.09	− 0.37	0.51	− 0.08	− 0.45	0.32
Semantic Verbal Fluency, z-score	0.40**	0.05	0.54	0.52**	0.24	0.72	− 0.01	− 0.24	0.22
Naming, z-score	0.64**	0.44	0.77	0.73**	0.53	0.85	0.43**	0.22	0.59
Verbal memory—total Learning, z-score	0.52**	0.29	0.69	0.74**	0.54	0.85	0.38**	0.17	0.56
Verbal memory—delayed recall, z-score	0.32**	0.05	0.55	0.44**	0.14	0.67	0.10	− 0.13	0.32
Verbal memory—intrusions, z-score	0.38**	0.12	0.59	0.37	0.05	0.62	0.40**	0.19	0.58
Verbal memory—recognition, z-score	0.22	− 0.05	0.47	0.33*	0.01	0.59	− 0.01	− 0.24	0.22
MRI visual ratings
Medial temporal atrophy (MTA) score	− 0.20*	− 0.54	− 01	− 0.66**	− 0.81	− 0.42	− 0.05	− 0.28	0.19
Posterior atrophy (Koedam) score	− 0.02	− 0.30	− 0.26	− 0.21	− 0.35	− 0.31	0.16	− 0.09	0.38
WHM severity (Fazekas score)	− 0.30*	− 0.54	− 0.02	− 25	− 0.54	0.09	0.17	− 0.07	0.39

CI, confidence interval; LL, lower limit; UL, upper limit; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment; WHM, White Matter Hyperintensities
*p < .05. **p < .001

ISSN: 2524-3489